Resurgent Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Resurgent Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-402	Closed	-$25.2K	–	253
2023 Q4	$25.2K	Buy	+402	New	+$22.2K	0.02%	451
2023 Q3	–	Sell	-412	Closed	-$23.1K	–	491
2023 Q2	$23.1K	Buy	+412	New	+$23.4K	0.02%	471
2023 Q1	–	Sell	-4,912	Closed	-$200K	–	517
2022 Q4	$200K	Sell	4,912 -240	-5%	-$12.7K	0.11%	204
2022 Q3	$336K	Buy	5,152 +431	+9%	+$31.2K	0.22%	122
2022 Q2	$287K	Buy	4,721 +451	+11%	+$26.5K	0.18%	140
2022 Q1	$268K	Buy	+4,270	New	+$268K	0.17%	138

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Resurgent Financial Advisors's CRSP Position: Q1 2024 in Review

Resurgent Financial Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 402 shares — an estimated $25.2K sold.

Resurgent Financial Advisors first reported a position in CRSP in Q1 2022 and held it in 6 quarters. The position peaked at $336K in Q3 2022. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

Resurgent Financial Advisors reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
Resurgent Financial Advisors sold 402 CRISPR Therapeutics shares in Q1 2024, an estimated $25.2K.
Resurgent Financial Advisors first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 6 quarters.
Resurgent Financial Advisors's CRISPR Therapeutics position peaked at $336K in Q3 2022.
484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Resurgent Financial Advisors's 13F filing for Q1 2024, filed 10 May 2024.